SCHEMBL2454438

SCHEMBL2454438

NC(=O)c1[nH]cnc1NCC(c1ccccc1)c1ccccn1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.42
CYP3A4 P08684 1/20 0.42
TSHR P16473 1/20 0.42
CYP2C19 P33261 1/20 0.42
KDM4E B2RXH2 1/20 0.42
LMNA P02545 1/20 0.42
RAB9A P51151 1/20 0.42
SLC6A3 Q01959 2/20 0.41
CHRM2 P08172 1/20 0.40
SLC6A2 P23975 1/20 0.40
SLC6A4 P31645 1/20 0.40
SCN1A P35498 1/20 0.40
SCN2A Q99250 1/20 0.40
SCN3A Q9NY46 1/20 0.40
CYP1A2 P05177 1/20 0.40
XDH P47989 3/20 0.39
GAA P10253 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2458114 0.73 PARP10 (0.41) ALDH1A1TSHRLMNARAB9ASLC6A2
SCHEMBL2454476 0.70 XDH (0.46) ALDH1A1TSHRKDM4ELMNAXDH
SCHEMBL6227388 0.70 ALDH1A1 (0.53) ALDH1A1CYP3A4TSHRCYP2C19KDM4E
SCHEMBL4253369 0.68 XDH (0.51) ALDH1A1TSHRKDM4ELMNAXDH
SCHEMBL29289278 0.67 ALDH1A1 (0.52) ALDH1A1CYP3A4TSHRCYP2C19KDM4E
SCHEMBL2458365 0.66 XDH (0.47) ALDH1A1CYP3A4TSHRKDM4ELMNA
SCHEMBL20777536 0.66 SLC6A2 (0.57) ALDH1A1CYP3A4TSHRCYP2C19KDM4E
SCHEMBL1131686 0.66 ALDH1A1 (0.55) ALDH1A1CYP3A4TSHRCYP2C19KDM4E
SCHEMBL17800898 0.65 SLC6A3 (0.62) TSHRLMNASLC6A3
SCHEMBL9812324 0.65 SLC6A2 (0.63) ALDH1A1CYP3A4TSHRCYP2C19KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2010535-B1 THIOXANTHINE DERIVATIVES AND THEIR USE AS INHIBITORS OF MPO ASTRAZENECA AB (SE) 2012-07-11 EP disclosed
US-8026244-B2 Thioxanthine derivatives and their use as inhibitors of MPO ASTRAZENECA AB (SE) 2011-09-27 US disclosed
US-20090149475-A1 Thioxanthine Derivatives and Their Use as Inhibitors of MPO ASTRAZENECA AB (SE) 2009-06-11 US disclosed
EP-2010535-A1 THIOXANTHINE DERIVATIVES AND THEIR USE AS INHIBITORS OF MPO AstraZeneca AB (SE) 2009-01-07 EP disclosed
WO-2007120098-A1 THIOXANTHINE DERIVATIVES AND THEIR USE AS INHIBITORS OF MPO ASTRAZENECA AB (SE) 2007-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149475-A1 Thioxanthine Derivatives and Their Use as Inhibitors of MPO MPO, XDH, EPX ALDH1A1 309/4885CYP3A4 1227/4885TSHR 723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.